Investing In Biotechnology Earnings Growth

Biotechnology was full of success stories in 2013. And some of those stories just got more exciting in February as the Nasdaq Biotech Index (IBB - Trend Report) rallied 13% off the lows. My FTM Portfolio also surged higher on the back of names like Pharmacyclics (PCYC - Trend Report)Medivation (MDVN - Trend Report), and Alnylam (ALNY - Trend Report)

But Alexion Pharmaceuticals (ALXN - Trend Report) was one of the heavy lifters of that IBB performance since it comprises nearly 5% of that index. ALXN shares rallied 17% this month to hit an all-time closing high of $181.52 after a strong quarterly report in late January that first vaulted the stock over 20% in one day from the low $130s to over $160. 

What was all the excitement about that had this biotech superstar making a $50 (nearly 40%) move in under 3 weeks? Sales and taxes, of course. 

Blockbuster Drug 
Alexion's revenues jumped 38% to approximately $442 million in the final quarter of 2013 -- beating the consensus by over $10 million -- driven by strong sales of their key drug Soliris, which is the only treatment available for paroxysmal nocturnal hemoglobinuria (PNH). 

PNH is a rare genetic blood disorder characterized by the onset of severe hemolytic anemia, chronic fatigue and intermittent episodes of dark colored urine, known as hemoglobinuria. Because of the life-saving benefits for these patients that only come from Soliris, major insurance companies support one of the highest price tags of any drug treatment at roughly $440,000. 

This may seem unfair to some minds, but Alexion was founded in 1992 and it's been a long and bumpy road to profitability. If biotech companies don't have visibility on potential financial outcomes, they cannot invest the billions in laboratory and clinical R&D necessary to discover specialized drug therapies that are both effective and safe in treating rare diseases that may only afflict a few thousand people. 

In 2011, the FDA cleared Soliris for treating children and adults suffering from atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disorder. In Nov 2011, a similar approval for the drug was granted in the EU. Japanese approval for the a HUS indication came in Sep 2013. 

Zacks Investment Research reports while Alexion is testing Soliris and a number of other compounds in a variety of different disease indications, the drug recorded sales of $1.55 billion in 2013, up 37%. 

1 2 3
View single page >> |

I'm not long or short any stocks listed in this article.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.